Neurogene
NASDAQ: NGNENew York, US · Founded 2018 · 6 known investors
Find your way into Neurogene
216 people in our graph share verified history with the Neurogene team — schools, employers, funds. One of them is your warm intro.
Robert Severounlockedknows Rachel McMinn · together at Cowen and Company (overlapped)
×6knows the team · via Piper Jaffray
×5knows the team · via Cowen and Company
Neurogene develops gene therapy treatments for rare neurological diseases. The company aims to make severe genetic neurological conditions treatable for patients and families impacted by these conditions.
Founders & leadership
Neurogene was founded in 2018 by Rachel McMinn and Rachel McMinn, Ph.D..
RM
Rachel McMinninFounder and Chief Executive OfficerRachel McMinn founded Neurogene in 2018 and serves as its President and CEO. She previously spent 17 years in biotechnology, including roles as Chief Business and Strategy Officer at Intercept Pharmaceuticals and as a biotechnology analyst at major financial institutions.
RM
Rachel McMinn, Ph.D.Founder and Chief Executive Officer
Board
CF
SB
Stephen BiggarBoard director
Investors · 6
Funding
SEC filings, press & company announcements$231.5M disclosed across 3 of 4 rounds · 2019–2026
- $125Mpublic offeringJul 2026 · 2 sources
Casdin Capital, EcoR1 Capital, Redmile Group, RTW Investments
Source ↗
▶$69MraisedDec 2020 · 32 investors · OtherRule 506(b)
▶$69MraisedDec 2020 · 32 investors · Other
Rule 506(b)Officers, directors & promoters on the filing
- Rachel McMinnExecutive Officer, Director
- Christine Mikail CvijicExecutive Officer
- Robert BaffiDirector
- Caroline StoutDirector
- Cory FreedlandDirector
- Srdjan StankovicDirector
- Stephen BiggarDirector
- Offering amount
- $115M
- Amount sold
- $69M
- First sale
- Dec 2020
- Incorporated
- Corporation, Delaware, 2018
- Federal exemptions
- 06b
▶$37.5MraisedFeb 2019 · 13 investors · OtherRule 506(b)
▶$37.5MraisedFeb 2019 · 13 investors · Other
Rule 506(b)Officers, directors & promoters on the filing
- Cory FreedlandDirector
- Rachel McMinnExecutive Officer, Director
- Stephen BiggarDirector
- Offering amount
- $37.5M
- Amount sold
- $37.5M
- First sale
- Feb 2019
- Incorporated
- Corporation, Delaware, 2018
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Valuation · disclosed
Disclosed events$110.5Mvaluation at IPOMar 2014 · $11.00/share · 424B4
filing ↗Source: SEC prospectus filings, and round valuations the company or its investors disclosed — follow each entry's link for the claim.
Competitors · 5
by search overlapThumbnail for Seragon Pharmaceuticals43 shared keywordsGenentech is a biotechnology company that develops and manufactures breakthrough medicines in the United States, backed by a $50 billion commitment to U.S. manufacturing and scientific innovation.
Biogen Idec35 shared keywordsBiogen is a biotechnology company founded in 1978 that focuses on breakthroughs in biology. The company serves patients through research and development in the life sciences industry.
Regeneron NASDAQ: REGN www.regeneron.com29 shared keywordsRegeneron is a biotechnology company that develops medicines ranging from biologics to genetic medicines to treat serious diseases across areas such as metabolic disease, ophthalmology, and rare disease. The company focuses on research and development driven by human biology, with a clinical trial pipeline addressing conditions like generalized myasthenia gravis.
NervGen Pharma22 shared keywordsNervGen is a clinical-stage biotech company developing therapies for neurological conditions, with a focus on spinal cord injury and neurorepair. It maintains a drug pipeline and operates as a publicly traded company.
Origene21 shared keywordsOriGene develops and supplies genomic and proteomic research tools, including proteins and antibodies built on its proprietary cDNA clone collections, for life science researchers. The company offers a broad catalog of research products used in scientific discovery and diagnostics development.
Companies competing with Neurogene for the same Google search keywords, organic and paid, via search-intersection analysis.
In the news
Neurogene Reports Second Quarter 2026 Financial Results and Highlights Recent Updates - BioSpacebiospace.com · Aug 2026
Neurogene (NGNE) widens loss yet raises $134.8M to fund Rett trialstocktitan.net · Aug 2026Frequently asked questions
- What does Neurogene do?
- Neurogene develops gene therapy treatments for rare neurological diseases. The company aims to make severe genetic neurological conditions treatable for patients and families impacted by these conditions.
- Who founded Neurogene?
- Neurogene was founded by Rachel McMinn, Rachel McMinn, Ph.D. in 2018.
- Who are Neurogene's investors?
- Neurogene's investors include EcoR1 Capital, Samsara BioCapital, Casdin Capital, REDMILE, RTW Investments L.P., William Blair.
- How much funding has Neurogene raised?
- Neurogene has disclosed $231.5M raised across 3 of its 4 known rounds.
- Where is Neurogene headquartered?
- Neurogene is headquartered in New York, US.